Sponsor of the Day:
Jerkmate
https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-paclitaxel-%c2%b1-bevacizumab-for-the-treatment-of-adults-with-pd-l1-cps-%e2%89%a51-platinum-resistant-recurrent-ovarian-carcinoma-wh/
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the...
Apr 6, 2026 - The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patients Approval supported by data from the...
european commissionapprovespembrolizumabpluspaclitaxel
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relacorilant-nab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian...
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
fda approvesnabpaclitaxelplatinumresistant
https://www.medtechdive.com/news/medtronic-confirms-paclitaxel-balloons-efficacy-in-post-approval-trial/817657/
Medtronic confirms paclitaxel balloon’s efficacy in post-approval trial | MedTech Dive
The end-stage kidney disease device performed as well in the study as in a pivotal trial that supported FDA approval.
post approvalmedtech divemedtronicconfirmspaclitaxel